Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations

Authors

Anthony H.V. Schapira, University College London
Stephen Mullin, Peninsula Medical School
Laura Smith, University College London
Katherine Lee, University College London
G D’Souza
Philip Woodgate, University College London
Josh Elflein, University College London
Jenny Hällqvist, University College London
Marco Toffoli, University College London
Adam Streeter, Peninsula Medical School
Joanne Hosking, Peninsula Medical School
Wendy E. Heywood, University College London
Rajeshree Khengar, University College London
Philip Campbell, University College London
Jason Hehir, University College London
Sarah Cable, University College London
Kevin Mills, University College London
Henrik Zetterberg, Sahlgrenska University Hospital
Patricia Limousin, University College London
Vincenzo Libri, University College London
Tom Foltynie, University College London

ORCID

• Stephen Mullin: 0000-0002-1936-394X
• Joanne Hosking: 0000-0001-7090-0205

DOI

10.1001/jamaneurol.2019.4611

Publication Date

2020-01-13

Publication Title

JAMA Neurology

ISSN

2168-6149

Embargo Period

2020-02-18

Recommended Citation

Schapira, A., Mullin, S., Smith, L., Lee, K., D’Souza, G., Woodgate, P., Elflein, J., Hällqvist, J., Toffoli, M., Streeter, A., Hosking, J., Heywood, W., Khengar, R., Campbell, P., Hehir, J., Cable, S., Mills, K., Zetterberg, H., Limousin, P., Libri, V., & Foltynie, T. (2020) 'Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations', JAMA Neurology, . Available at: 10.1001/jamaneurol.2019.4611